A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.

NCT04722679 · clinicaltrials.gov ↗

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Valvular Atrial Fibrillation

Interventions

DRUG: Non-VKA Oral Anticoagulants (NOAC)

Sponsor

Bayer